SOUTH SAN FRANCISCO, Calif., April 19 /PRNewswire-FirstCall/ -- Anesiva, Inc. announced today that John P. McLaughlin, the company’s chief executive officer, will present at the 7th Annual Fortis Biotechnology Conference in London on April 25, 2007 at 3:30 p.m. GMT.
To access the live webcast or the subsequent archived recording, log on to http://www.anesiva.com and go to the Investors page, and click on Events. Please connect to Anesiva’s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has two drug candidates in development for multiple pain-related indications. A New Drug Application (NDA) has been filed for the most advanced product, Zingo(TM). The second product in the pipeline, 4975, has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva’s leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.
Anesiva, Inc.
CONTACT: Jennifer Cook Williams, Vice President, Investor Relations ofAnesiva, +1-650-624-9600, or investors@anesiva.com
Web site: http://www.anesiva.com//
